Q3 2012 results - October 25, 2012
|Net sales||13 807||14 843||-7 (cc: -2)|
|Operating income||3 027||2 951||3 (cc: 5)|
|Net income||2 476||2 488||0 (cc: 2)|
|EPS (USD)||1.01||1.02||-1 (cc: 2)|
|Free cash flow2||3 503||3 675||-5|
|Operating income||3 889||4 112||-5 (cc: -3)|
|Net income||3 260||3 539||-8 (cc: -6)|
|EPS (USD)||1.34||1.45||-8 (CC: -6)|
- Constant currencies
- Core results and free cash flow are non-IFRS measures. See media release for further information.
The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.